Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Accenture
Johnson and Johnson
Queensland Health
US Department of Justice
Citi
Covington
Fuji
Deloitte
Medtronic

Generated: August 23, 2017

DrugPatentWatch Database Preview

Janssen R And D Company Profile

« Back to Dashboard

What is the competitive landscape for JANSSEN R AND D, and when can generic versions of JANSSEN R AND D drugs launch?

JANSSEN R AND D has two approved drugs.

There are four US patents protecting JANSSEN R AND D drugs.

There are one hundred and thirty-four patent family members on JANSSEN R AND D drugs in thirty-nine countries.

Summary for Applicant: Janssen R And D

Patents:4
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-002Dec 22, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-001Jan 18, 2008RXYesNo► Subscribe► SubscribeYY ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-003Mar 26, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-002Dec 22, 2010RXYesYes► Subscribe► SubscribeYY ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-002Dec 22, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Janssen R And D

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,530,655HIV replication inhibiting pyrimidines► Subscribe
7,241,458Antiviral compositions► Subscribe
6,638,932 2,4-disubstituted triazine derivatives► Subscribe
7,015,2212,4-disubstituted triazine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Janssen R And D Drugs

Country Document Number Estimated Expiration
Slovenia1002795► Subscribe
Iceland6256► Subscribe
Ukraine74797► Subscribe
Austria315031► Subscribe
Norway318801► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Janssen R And D Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1002795/01Switzerland► SubscribePRODUCT NAME: ETRAVIRIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58483 13.05.2008
2009 00004Denmark► Subscribe
0373Netherlands► Subscribe300373, 20191101, EXPIRES: 20230827
2009000003Germany► SubscribePRODUCT NAME: ETRAVIRIN UND DESSEN ADDITIONSSALZE; REGISTRATION NO/DATE: EU/1/08/468/001 20080828
C/GB09/003United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/003 GRANTED TO JANSSEN PHARMACEUTICA NV IN RESPECT OF THE PRODUCT ETRAVIRINE OPTIONALLY IN A FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6342 DATED 08 DECEMBER 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 AUGUST 2023.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Farmers Insurance
Queensland Health
Medtronic
McKesson
Dow
Novartis
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot